Inclusive of all taxes
Glimepiride & Metformin Prolonged Release Tablets IP are a specifically formulated combination pharmaceutical product designed for the effective management of type 2 diabetes mellitus. This product merges two potent antidiabetic agents—Glimepiride, a sulfonylurea that stimulates insulin secretion, and Metformin, a biguanide that improves insulin sensitivity, into a prolonged release (PR) dosage form ensuring sustained therapeutic action, better glycemic control, and enhanced patient compliance. Manufactured under stringent WHO-GMP compliant processes in India by IndiGlobal Exports, these tablets meet IP (Indian Pharmacopoeia) standards suitable for international pharmaceutical markets. The extended-release formulation maintains steady plasma drug concentrations over an extended period, minimizing dosing frequency and reducing side effects often associated with conventional immediate-release formulations. Packaged in export-grade blister or strip packs, the tablets assure product safety, integrity during shipment, and convenience in dispensing. Ideal for hospitals, pharmacies, and distributors catering to regulated and semi-regulated markets, this product guarantees consistency, high therapeutic efficacy, and adherence to global regulatory norms.
Key Features
| Features | Description |
|---|---|
| Combination Therapy | Contains Glimepiride and Metformin for dual-action glycemic control |
| Prolonged Release Formulation | Sustained drug release ensuring consistent plasma drug levels |
| Indication | Treatment of type 2 diabetes mellitus |
| Manufacturing Standards | Produced in WHO-GMP compliant facilities meeting IP standards |
| Packaging | Export-grade blister or strip packs to ensure product safety during transport |
| Therapeutic Reliability | Ensures consistent efficacy and safety for diabetic management |
| Suitable Markets | Compliant with international healthcare regulations for export |
| Manufacturer | IndiGlobal Exports |
| Attributes | Description |
|---|---|
| Category | Diabetes Treatment |
| Dosage Form | Prolonged Release Tablet |
| Active Ingredients | Glimepiride, Metformin |
| Shelf Life | As per regulatory standards (typically 24-36 months) |
| Packaging Type | Blister or strip packs - export grade |
| Pharmacopoeia Compliance | Indian Pharmacopoeia (IP) standards |
| Manufacturing Compliance | WHO-GMP certified facilities |
| Intended Use | Clinical treatment and management of diabetes mellitus |
| Export Readiness | Formulated and packaged per international export norms |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The prolonged release formulation provides a steady release of Glimepiride and Metformin over time, enhancing glycemic control, reducing dosing frequency, and minimizing side effects compared to immediate-release forms.
Yes, these tablets are manufactured in WHO-GMP compliant facilities and adhere to Indian Pharmacopoeia standards, making them suitable for export to regulated and semi-regulated international markets.
The tablets are available in export-grade blister packs or strip packs designed to maintain product integrity and facilitate safe transportation during bulk export.
Yes, due to their compliance with strict quality and safety standards, these tablets are ideal for both hospital prescriptions and retail pharmacy distributions.
The shelf life is as per regulatory guidelines, usually ranging between 24 to 36 months, ensuring stability and efficacy throughout the storage period.
Glimepiride & Metformin Prolonged release Tablets IP is a pharmaceutical product indicated for diabetes treatment. This formulation is manufactured with export-quality standards to ensure therapeutic efficacy, consistent dosage, and compliance with international healthcare regulations.
Features:Glimepiride & Metformin Prolonged release Tablets IP is developed for the effective management of diabetes conditions, offering reliable performance backed by stringent pharmaceutical standards. Each batch is carefully produced and tested to ensure consistency, safety, and compliance with global export norms.
This formulation supports the clinical treatment and ongoing care of patients with diabetes indications. Commonly prescribed in hospital and retail pharmacy settings, it ensures measurable therapeutic benefit.
Crafted in state-of-the-art facilities, this tablet formulation ensures accuracy in dosing and ease of administration. It is typically available in secure blister or strip packs suitable for bulk export or institutional supply.
The product is manufactured in facilities adhering to WHO-GMP standards and complies with pharmacopoeial quality benchmarks (IP/USP). Ideal for regulated and semi-regulated markets seeking quality-assured medications.
Inclusive of all taxes
You Save: 0
Panchkula , India
Service Provider , Professional Services, Exporter, Wholesaler
GST- 06EOGPS3248L1ZF
